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Summary Twelve patients with small cell lung cancer were treated with recombinant human granulocyte
colony-stimulating factor, rhG-CSF, given by continuous infusion at doses ranging from 1 to
40 igkg-'day-'. Patients received the rhG-CSF before the start of intensive chemotherapy and after alternate
cycles of chemotherapy. Several in vitro assays were performed using peripheral blood neutrophils and
marrow progenitor cells collected from patients prior to and after infusion of the growth factor. Peripheral
blood neutrophils were tested for mobility and phagocytic activity. In addition, in vitro clonogenic assays of
marrow haemopoietic progenitor cells and analysis of bone marrow trephines and aspirates were carried out.
We found that rhG-CSF in vivo has at least two main effects: (a) an early fall in peripheral neutrophils,
within the first hour, followed by a rapid influx of mature neutrophils into the circulatory pool; (b)
stimulation of proliferation and differentiation of neutrophil precursors in the bone marrow. Neutrophils
released into the circulation were normal in tests of their mobility and phagocytic activity.
In recent years a variety of growth factors have been
described which stimulate the proliferation and
differentiation of multipotent and lineage-restricted haemo-
poietic progenitor cells in vitro (Metcalf, 1986; Sieff, 1987)
and promote the functional activation of mature cells
(Fleischmann et al., 1986; Nicola, 1987).
The genes for many of these growth factors have been
molecularly cloned and their products expressed in bacteria.
The large amount of material thus generated has allowed an
analysis of the effects of these growth factors when
administered in vivo. Stimulation of granulopoiesis in vivo by
recombinant human granulocyte colony-stimulating factor
(rhG-CSF, Souza et al., 1986) has been documented in mice
by Moore & Warren (1987), who also showed a synergy of
this growth factor with interleukin-1, and in monkeys by
Welte et al. (1987). Granulocyte-macrophage colony-
stimulating factor has been shown to stimulate haemopoiesis
in vivo both in animals (Donahue et al., 1986) and in
patients (Groopman et al., 1987; Vadhan-Raj, et al., 1987).
We have demonstrated the value of a colony-stimulating
factor, rhG-CSF, in reducing the period of neutropenia (by a
median of 80%) in patients treated with intensive chemo-
therapy, with a parallel protective effect against severe
infections (Bronchud et al., 1987). In this study, twelve
patients with small cell lung cancer received recombinant
human granulocyte colony-stimulating factor (rhG-CSF)
given by continuous infusion before the start -and after
alternate cycles of intensive chemotherapy.
Here we present the time course of response to rhG-CSF
in these patients as well as neutrophil function tests, bone
marrow clonogenic assays and histology before and after the
infusion of growth factor.
Materials and methods
Patients
Twelve patients with advanced small cell lung cancer gave
their informed consent to enter the study, under the guide-
lines of the district medical ethics committee. The study
design has been described in our previous paper (Bronchud
et al., 1987). Briefly, whenever possible, each patient
participated in a phase I and phase II study. The former
Correspondence: M.H. Bronchud.
Received 15 February 1988; and in revised form 19 April 1988.
consisted of a five days continuous infusion of rhG-CSF to
assess toxicity and effect on bone marrow and peripheral
blood counts. This was followed by a phase II study
consisting of intensive chemotherapy, with patients acting as
their own control, receiving rhG-CSF, at the same dose as
used in the phase I, after alternate courses of cytotoxic
chemotherapy. Any patient unable to progress to the phase
II was replaced by another patient at the same dose level
and was identified by adding R (for replacement) to his/her
study number. Patient study numbers, number of chemo-
therapy cycles received and rhG-CSF doses are shown in
Table I. Patient no. 5 was withdrawn at the end of the phase
I part of the study because she required palliative radio-
therapy for pain control, and patient no. 8 was unable to
receive chemotherapy because of an insufficient creatinine
clearance. Patient no. 7, who had particularly advanced
disease at presentation, died shortly after completing her first
chemotherapy treatment, and before the phase II rhG-CSF
infusion, from respiratory failure. Her post-mortem
confirmed multiple hepatic and bony metastases, a large
bronchial carcinoma and pulmonary oedema as a terminal
event. Patient 7R proved to have a carcinoid tumour. Also
shown in Table I are the mean absolute neutrophil counts
(ANC) for each patient during the cycles with or without
rhG-CSF infusion, as well as the survival of patients and
their response to chemotherapy.
Polymorph function tests
Cells Leucocyte populations from peripheral blood were
prepared by dextran sedimentation of heparinised blood and
residual red cells removed by H20 lysis. Cells were washed
twice in Hanks balanced salt solution (Flow Labs),
resuspended in HEPES buffered RPMI-H medium (RPMI
1640, Flow Labs) and counted on a haemocytometer.
Polymorph phagocytic function Phagocyte function was
measured essentially as described by Easmon et al. (1980) by
the technique of luminol-dependent chemiluminescence using
zymosan as the stimulating agent. The test was performed
using disposable polystyrene cuvettes (Clinicon) containing
700,yl luminol (Sigma) 10-4M in RPMI-H, 200yl of freshly
opsonised zymosan (Zymosan A, Sigma) and 1OOjI cell
suspension (containing 5 x 106 polymorphs ml-'). Control
tubes contained RPMI-H instead of zymosan. Cuvettes were
counted repeatedly at 3min intervals for 30min using a LKB
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1251 Luminometer and the results expressed as mean values
for the peak chemiluminescence (in mV). All samples were set
up in duplicate and a control blood sample was tested
simultaneously with each patient sample.
Polymorph chemotaxis Polymorph mobility was measured
by the technique of migration under agarose essentially as
described by Nelson et al. (1975). Briefly, agarose plates
(0.75% agarose in RPMI-H supplemented with 10% pooled
human plasma and 2mM glutamine) were punched to give 6
groups of 3 wells (3mm wells with 3mm between wells). The
centre well in each group of 3 was filled with 10MI cell
suspension (adjusted to give 5x 105 polymorphs/well). One
of the remaining wells was filled with 101 RPMI-H and the
other with 10,ul chemotactic agent (N-formyl-methionyl-
leucyl-phenylalanine, Sigma) at 6 concentrations (10-6 M
and serial 2-fold dilutions). Migration distances towards the
control (medium) well and the chemotactic agent were
measured after 2 h at 37 C (in 5% CO2) under the microscope
using a calibrated eycpiece, and values were expressed in
mm x 102 as a specific migration distance by subtracting the
control distance from the chemotactic distance. In each test a
normal control blood sample was tested simultaneously with
the patient's sample.
In vitro survival of peripheral neutrophils Different concen-
trations of leucocytes from rhG-CSF treated patients and a
normal control, purified by density-gradient centrifugation of
a leucocyte cell suspension over Lymphoprep separation
medium (Nycomed) to deplete mononuclear cells, were
plated with and without rhG-CSF (3 x 10i Uml-1) and live
cell numbers were counted on a haemocytometer after
staining with Trypan blue over a period of 6 days.
Neutrophil alkaline phosphatase The activity of this enzyme
was determined daily during the phase I part of the study as
described by Rutenberg (1965). A normal blood film and a
blood film giving a strong reaction were used as controls.
Clonal assays for haemopoietic cells
All methods were essentially as described before (Metcalf,
1977; Testa, 1985) with minor modifications.
Cells Bone marrow cells were obtained by aspiration from
the posterior superior iliac crest before and after 5 days of
continuous infusion of rhG-CSF (via central line) during the
phase I part of our study. Cells were collected in Iscove's
medium (Gibco) with 40ml-1 of preservative free heparin
(sodium heparin Weddel Pharmaceuticals Ltd.) and red
blood cells were separated by sedimentation in 0.1% methyl-
cellulose over 30min at room temperature.
Clonogenic haemopoietic progenitor cell assay Bone marrow
cells were plated at 105 cellsml- in 0.9% methylcellulose,
20% conditioned medium from the 5637 carcinoma cell line
(as a source of colony-stimulating factors, Myers et al., 1984),
2 Units of partially purified urinary erythropoietin (Terry
Fox Lab, Vancouver), with a final concentration of 1%
bovine serum albumin (Sigma) and 10% foetal calf serum
(FCS, Flow Lab) in Iscove's medium. Triplicate 1 ml aliquots
were cultured in MultiwellTM tissue culture plates (Falcon) for
14 days under fully humidified conditions in an atmosphere
of normal 02 concentration at 37°C. Recognisable erythroid
colonies were labelled as BFU-E (Burst Forming Unit-
Erythroid) and myeloid colonies as GM-CFC (Granulocyte
Macrophage-Colony Forming Cells) if >50 cells per aggre-
gate. The ratio GM-CFC/BFU-E was calculated for each
patient before and after the infusion of rhG-CSF and the
results were analysed by the Wilcoxon matched-pairs signed-
ranks test. All assays were performed with and without
adherent bone marrow cells and in some experiments the
in vitro response to rhG-CSF was tested by adding
3 x 103 Uml- of rhG-CSF (AMGen) to the above medium
mixture in the absence of conditioned medium. Adherent cell
depletion was performed by incubating red blood cell de-
pleted human bone marrow cells in Falcon tissue culture
flasks at 106cellsml-' for 2h at 37°C. Thereafter, the
medium was collected and the cells counted and used for
clonogenic assays as before.
Tritiated thymidine suicide assay 3H-TdR suicide, modified
from Becker et al. (1965), was used to determine the
percentage of clonogenic haemopoietic progenitor cells in the
S-phase of the cell cycle. Paired 1 ml aliquots of 5 x 106 red
cell depleted bone marrow cells were incubated for 30min at
37°C in the presence of either 200pCiml-1 3H-TdR, of
specific activity 555GBqmmol-1 (Amersham), or an equal
volume of medium. Incorporation of 3H-TdR was stopped
by placing the cells on ice for 5min, and washing them twice
in Iscove's medium containing 10% FCS and 100lgml-1
unlabelled thymidine. Thereafter, the cells were assayed for
clonogenic cells by plating them at 1 x io1 cells in 1ml of
0.3% agar that included Iscove's medium supplemented with
a final concentration of 15% FCS and 20% conditioned
medium from the 5637 bladder carcinoma cell line in 35mm
plastic Petri dishes (Falcon). Cultures were scored for
colonies after 11 days of incubation under fully humidified
conditions in an atmosphere of air plus 5% CO2 at 37°C.
The Standard Kill error was calculated as described by Lord
& Schofield (1985) and results before and after the infusion
of rhG-CSF were analysed by the Wilcoxon matched-pairs
signed-ranks test.
Bone marrow trephines
Bone marrow trephines were obtained under local
anaesthetic from the posterior superior iliac crest before and
after 5 days of continuous infusion of rhG-CSF (phase I) or
when clinically indicated. They were fixed in 10% formol
saline and decalcified overnight in 15% formic acid. Finally,
they were processed to paraffin wax, cut and stained with
hematoxylin and eosin. Trephines were examined at x 10
magnification to determine marrow cellularity. An assessment
of percentage of area occupied by haematopoietic tissue was
made visually using coded slides. Replicate estimates
generally gave results within 10% of each other.
Bone marrow aspirates were obtained at the same time as
bone marrow trephines and smears were stained conven-
tionally with May-Grumwald-Giemsa. The myeloid-erythroid
ratios and differential counts were determined for each
patient, and results analysed by the Wilcoxon matched-pairs
signed-ranks test.
Results
All 12 patients in our study responded to rhG-CSF with a
specific increase in peripheral neutrophils (6 to 10-fold) up to
a maximum of 100 x1091- 1 at lOjpgkg- l day-1 of rhG-
CSF. There were no appreciable changes in monocytes,
eosinophils, platelets, lymphocytes or haemoglobin
(Bronchud, et al., 1987).
As shown in Figure 1, following infusion of rhG-CSF,
there was a rapid but selective and transient fall in the
number of peripheral neutrophils, followed by an increase 2
to 8 h later. We have shown previously (Bronchud et al.,
1987) that the increase in peripheral neurophils was main-
tained for as long as the infusion of rhG-CSF continued, but
the counts fell back to normal levels within 24 to 48h after
stopping the growth factor infusion.
Table II shows that peripheral neutrophils after 3 days of
rhG-CSF infusion were normal in tests of their mobility and
phagocytic functions. The latter (as reflected by the chemi-
luminescence values) was usually increased (up to 2-fold) by
rhG-CSF treatment and when it reached high values, neutro-
phil mobility appeared slightly reduced. Similar results were
also obtained with peripheral neutrophils from rhG-CSF66 M.H. BRONCHUD ci al.
Table I Patients study numbers, number of chemotherapy cycles received dose of
rhG-CSF given, mean absolute neutrophil counts (ANC) at day 15, from day 1 of
chemotherapy, on and off rhG-CSF infusion are shown. CT=chemotherapy, which
consisted of i.v. adriamycin (50mgm-2), i.v. etoposide 120mgm 2 (x 3) and ifosfamide
5gm-2 (with mesna) given by i.v. infusion. Chemotherapy cycles were repeated every 3
weeks. Survival is measured from the date of histological diagnosis. PR=partial response;
CR=complete response; NR=no response; ECR=equivocal complete response (minimal
residual abnormalities on chest X-ray). Asterisks (*) denote patients still alive and on
follow up
Dose of ANC at day 15
No. of CT rhG-CSF Survival
Pt. cycles (ygkg-'day-1) On G-CSF Off G-CSF (months) Response to CT
2
3
4
5
SR
6
7
7R
8
8R
9
4
6
6
6
None
4
3
None
2
None
4
4
1
1
5
5
10
10
10
20
20
20
20
40
12,000
22,590
72,224
24,323
ND
36,000
18,900
ND
27,482
ND
31,185
34,000
211
433
295
110
64
616
40
255
200
5
10
10
9
5
12
3
3 wks
3
3
7
PR
CR
CR*
CR*
CR*
PR
PR (carcinoid)
NR
ECR*
The number of infective complications requiring i.v. antibiotics were ten during the cycles
of chemotherapy which did not include rhG-CSF, while only one infective episode
occurred when patients were treated with rhG-CSF, and this was a bronchopneumonia in
a non-neutropenic patient who had bronchial obstruction by tumour (8R).
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Table II Granulocyte function tests. Tests are shown for all
12 patients before (DO) and after 3 days (D3) of continuous
infusion of the rhG-CSF. Peripheral neutrophils from patients
3 and 6 tested at the time of recovery from the nadir
following chemotherapy showed chemiluminescence values of
2,542 and 2,731 respectively, with a migration distance of 71
and 40. The nominal range for chemiluminescence in our
laboratory is wide (>750mV) and for migration distance is
96-200mm x 102
Chemiluminescence Peak migration distance
(Units=mV) (mm x 102)
Pt. DO D3 DO D3
1 1,324 2,380 136 120
2 1,454 1,818 160 104
3 1,377 1,347 184 136
4 1,649 3,186 136 59
5 1,179 2,426 152 88
SR 955 1,837 144 144
6 1,829 2,552 168 104
7 1,697 3,481 184 96
8 1,296 2,230 120 160
8R 1,324 3,439 152 96
9 2,306 ND 152 ND
XI//
V/
0 1
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Figure 1 Composite figure showing tim4
rhG-CSF in patients 2 (0), 4 (A), 8R (x)
8R and 9 (solid lines) had blood samples
30min, 1 h and 2h after the start of the infu
and illustrate the early fall in absolute neutr
2 and 4 (dashed lines) had blood samples ta
and later intervals and illustrate the i
neutrophil count. No changes were seen
A.N.C.=absolute neutrophil count mm-3.
were shown in our previous paper (Bronch
treated patients (patients 3 and 6) at 1
from the nadir following chemothera
protective effect in vivo was suggested by
the number of infective complications
biotics were ten during the cycles of chemotherapy which did
not include rhG-CSF, with positive blood cultures in three
, patients, while only one infective episode occurred when
16 20 24 patients were treated with rhG-CSF, and this was a broncho-
pneumonia in a non-neutropenic patient who had not
e-response curves to responded to chemotherapy (Bronchud, et al., 1987; and
and 9 (0). Patients Table I).
taken at zero time, We decided to investigate whether rhG-CSF can confer an
sion of growth factor increased survival to peripheral neutrophils (Figure 2). In
ophil counts. Patients this experiment peripheral blood leucocytes obtained from
aken at zero time, 2h patients during rhG-CSF treatment exhibited similar survival
increase in absolute kinetics, with or without added rhG-CSF, to those obtained
in other cell counts. from normal volunteers when cultured in vitro. However, we
Dose-response curves also found that when peripheral blood leucocytes were iud et al., 1987). cultured from patients who had received rhG-CSF, the
numbers of polymorphs recovered after 24h was higher than
the time of recovery the original value (Figure 2). This presumably reflects
Lpy (day 15). Their contamination of the peripheral blood leucocytes with a
the observation that significant number of proliferatively active myeloid precursor
requiring i.v. anti- cells as a result of the in vivo treatment with rhG-CSF. In
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Figure 2 In vitro survival of peripheral leucocytes. Peripheral
leucocytes from a patient treated with rhG-CSF (solid lines) and
from a normal control (dashed lines) were incubated in vitro at
different cell concentrations in the presence (full symbols) or
absence (open symbols) of added rhG-CSF (3 x 103Uml- 1). Cells
were plated at the following concentrations: OL: 4 x 106ml-, 0:
2 x 106ml- 1,A: 106ml-'. The patient's differential count at zero
time showed 4% myelocytes.
fact, most patients receiving 10-40 pgkg-'day-' rhG-CSF
had a median of 4% of peripheral metamyelocytes (range 1-
15%) after -48h and 2% myelocytes (range 1-4%) after 4
days of growth factor infusion. More importantly, however,
no blast cells were ever seen. This contamination of peripheral
blood leucocytes by immature forms might also help to
explain the reduction in neutrophil mobility found in patients
3 and 6 on recovery from the nadir induced by chemo-
therapy, since both patients had significant numbers of
immature forms at the time of sampling (10% and 14%
respectively).
The neutrophil alkaline phosphatase activity also increased
in all patients after
- 48h of rhG-CSF infusion, up to a
maximum of 389 at 10 pgkg- day-1 (normal range is
15-100).
Another measure of dynamic changes in response to rhG-
CSF was shown by the hypercellularity seen in bone marrow
trephines of all patients following growth factor treatment
during the phase I part of the study (Figure 3). Coded
samples taken before and after the infusion of growth factor
could be easily distinguished, and the median absolute
increase in cellularity was 20% (from 30% pre-therapy to
50% post). A bone marrow trephine was also obtained from
patient 4 when rhG-CSF was given after the sixth and last
cycle of chemotherapy and showed a comparable degree of
hypercellularity at the time of recovery from the chemo-
therapy induced neutrophil nadir. The proportion of cycling
haemopoietic progenitor cells (Table III) was only slightly
increased by rhG-CSF treatment (median of 8.5%, P=0.028).
The GM-CFC/BFU-E ratio was not statistically different
(P =0.25) after 5 days of rhG-CSF infusion (Table III).
However, the myeloid-erythroid ratio in bone marrow
aspirates was significantly raised (P=0.028), up to 5-fold pre-
treatment values, by the growth factor infusion (Table IV).
We found no evidence of a stimulatory effect of rhG-CSF
on small cell lung cancer. Thus a repeat bone marrow
Figure 3 Staining of bone marrow trephines from patient 4
before (a) and after (b) 5 days of rhG-CSF infusion at
5Sugkg-1day- '. (H&E, x6.3).
Table III Bone marrow in vitro assays. Haemopoietic
progenitor cells in S-phase (%) (in 0.3% agar with
15% FCS and 20% conditioned medium) and GM-
CFC/BFU-E ratios (in 0.9% methylcellulose with 10%
FCS, 20% conditioned medium and 2U erythro-
poietin) are shown before (DO) and after (D5) 5 days
of continuous infusion of rhG-CSF. The values shown
as % of haemopoietic progenitor cells in S-phase are
the calculated mean; the standard kill error was
< +5% for all tests. The range of % of haemopoietic
progenitor cells in S-phase for 3 normal controls was
35-49%. Asterisks (*) denote bone marrows histo-
logically involved by small cell lung cancer
% in S-phase GM-CFC/BFU-E ratio
Pt. DO D5 DO D5
1 63 73 0.71 4.0
2 43 49 1.6 2.1
3 50 68 0.88 1.9
4* 40 47 2.2 2.8
5 85 ND 3.3 ND
5R* 64 69 1.26 2.2
6 49 ND 1.8 ND
7* 59 73 4.8 2.6
8* 43 ND 3.2 ND
Table IV Myeloid-erythroid ratios in bone
marrow aspirates from patients 1-6 before
and after 5 days of rhG-CSF infusion
rhG-CSF treatment
Pt. Pre- Post-
1 5.5/1 6.8/1
2 3.2/1 5.8/1
3 4.2/1 4.4/1
4 5.5/1 26.3/1
5 3.6/1 7.2/1
6 3.1/1 5.1/168 M.H. BRONCHUD et al.
trephine in one of our patients (performed on the same site),
with pre-treatment extensive replacement by small cell
carcinoma cells, revealed no malignant cells following chemo-
therapy and rhG-CSF treatment. Although the numbers are
obviously small, a complete remission rate of 50% (Table I)
compares favourably with the best published series for
advanced small cell lung cancer (Spiro, 1985). The median
survival of the 8 evaluable patients with histologically proven
advanced small cell lung cancer is now 8 months and 4
patients remain alive and on follow up (Table I). Small cell
carcinoma cells were grown in vitro from the bone marrow of
another patient, but did not respond to the presence of rhG-
CSF in the medium and they died within 10 days.
One patient died during the study while receiving rhG-
CSF (8R) and microscopic evidence of some extramedullary
haemopoiesis in the spleen was found at post-mortem.
Discussion
Our results suggest that rhG-CSF in vivo has at least two
main effects: (a) an early fall in peripheral neutrophils within
the first hour, followed by a rapid influx of mature
neutrophils into the circulatory pool; (b) stimulation of
proliferation and differentiation of neutrophil precursors in
the bone marrow.
The early influx occurs between 2 and 8 hours after the
start of the continuous infusion of rhG-CSF (Figure 1) and is
specific for neutrophils. Initially, only mature neutrophils are
released into the circulation, but at high doses of rhG-CSF
some metamyelocytes and myelocytes are also seen in the
peripheral blood after 2 or 3 days. This response is quite
different from the biphasic leucocyte changes which are seen
following the parenteral administration of epinephrine
(Samuels, 1951) which causes a prompt mobilisation of all
white cell elements (maximal within 20 minutes) thought to
be secondary to demargination of leucocytes from post-
capillary venules. In fact, during the first hour of the rhG-
CSF infusion we found a transient decrease in peripheral
neutrophils with no significant change in other circulating
cell numbers. The reason for this initial decrease is unclear
and requires further investigation, but it might be related to
migration of circulating neutrophils into tissues or to
increased adherence of neutrophils to endothelium. Similar
findings have been recently reported by Morstyn et al. (1988)
following rhG-CSF given by short intravenous infusion. The
subsequent rise in peripheral neutrophils produced by rhG-
CSF is probably due to an increase in the influx of cells from
the bone marrow (both mature and de novo granulocytes).
This is similar to one of the mechanisms proposed for
cortisone-induced neutrophil leucocytosis, but the latter is
also known to result from a decreased efflux of cells from the
blood (Bishop et al., 1968), and it is not associated with a net
increase in the rate of bone marrow neutrophil production
(Vincent, 1977).
It is possible that part of the explanation for the increased
neutrophil count is due to prolonged survival of myeloid
cells in the presence of rhG-CSF. Our analysis in vitro
suggests that the growth factor does not significantly prolong
survival of either control cells or cells obtained from patients
treated with growth factor. However, a marginal increase in
neutrophil survival in vitro, between 24 and 40 hours, has
been reported by Begley et al. (1986) when neutrophils were
plated at much lower densities in the presence of purified
murine G-CSF. We did not look for such effect. The finding
that peripheral neutrophil counts in patients return to
normal levels within 24-48 hours after stopping the growth
factor infusion also agrees with the best estimates of the
normal half-life of circulating neutrophils in vivo (about 8
hours, Vincent, 1977), as one would expect a minimum of 4
half-lives to elapse before blood counts return to normal by
a process of gradual cell loss.
The increased cellularity seen after 1 day following culture
of cells from patients treated with rhG-CSF probably
reflects the presence of proliferating precursor cells in peri-
pheral blood at the time of sampling, and does not appear to
be influenced by the addition of rhG-CSF to the in vitro
cultures. Thus, while the initial increase in peripheral
neutrophils in vivo almost certainly reflects a release of
myeloid cells from the bone marrow, the sustained increase
presumably reflects increased proliferative activity in the
bone marrow, rather than more prolonged survival of
circulating cells.
Indeed, this stimulation of haemopoiesis in vivo in the
bone marrow was directly demonstrated by the 20% increase
in bone marrow cellularity seen in bone marrow trephines
after the infusion of growth factor and by a significant
increase in the myeloid-erythroid ratio in bone marrow
aspirates. Bone marrow cellularity at the time of recovery
from the chemotherapy induced neutrophil nadir (day 15)
when rhG-CSF was given after the sixth and last chemo-
therapy cycle was similar to that observed after the infusion
of growth factor during the phase I part of the study. Most
of the expansion in cell numbers probably occurs after the
GM-CFC stage, as the increase in the proportion of cycling
haemopoietic progenitor cells was only small (median of
8.5%). However, we cannot exclude a fractional stimulatory
effect of rhG-CSF on GM-CFC cells in patients, as the GM-
CFC/BFU-E ratio was often slightly increased after growth
factor treatment, although this increase did not reach
statistical significance. Of course, the presence of other
factors, such as interleukin-l(IL-1), in patients with
advanced lung cancer is likely, and the known interactions
between IL-1 and rhG-CSF (Moore & Warren, 1987)
preclude any simplistic interpretation in the in vivo effects of
rhG-CSF.
The median survival of the eight evaluable patients with
histologically proven advanced small cell lung cancer in this
study is now 8 months and four patients remain alive and on
follow up. This survival is consistent with that of currently
employed chemotherapy regimes (Aisner, 1987).
Our results in patients suggest that, when given as a
continuous infusion at 1-40ugkg-1day-1, rhG-CSF results
in a specific increase in peripheral neutrophils and neutrophil
precursors.
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